{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Solution&page=18",
    "query": {
      "intervention": "Control Solution",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 3229,
    "total_pages": 323,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Solution&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Solution&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T12:29:05.033Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00928083",
      "title": "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria Falciparum",
        "Malaria Vivax",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "OZ439 50mg API capsules",
          "type": "DRUG"
        },
        {
          "name": "OZ439 200mg API capsules",
          "type": "DRUG"
        },
        {
          "name": "OZ439 400mg aqueous dispersion",
          "type": "DRUG"
        },
        {
          "name": "OZ439 800mg aqueous dispersion",
          "type": "DRUG"
        },
        {
          "name": "OZ439 100mg API capsules",
          "type": "DRUG"
        },
        {
          "name": "OZ439 400mg API capsules",
          "type": "DRUG"
        },
        {
          "name": "OZ439 1600mg aqueous dispersion",
          "type": "DRUG"
        },
        {
          "name": "OZ439 800mg API capsules",
          "type": "DRUG"
        },
        {
          "name": "OZ439 1200mg API capsules",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "OZ439 200mg aqueous dispersion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medicines for Malaria Venture",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 63,
      "start_date": "2009-04",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2015-01-08",
      "last_synced_at": "2026-10-23T12:29:05.033Z",
      "location_count": 1,
      "location_summary": "Miramar, Florida",
      "locations": [
        {
          "city": "Miramar",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00928083"
    },
    {
      "nct_id": "NCT02780583",
      "title": "Treatment of Macrophage Activation Syndrome (MAS) With Anakinra",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Macrophage Activation Syndrome"
      ],
      "interventions": [
        {
          "name": "kineret",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 9,
      "start_date": "2016-05-15",
      "completion_date": "2024-04-30",
      "has_results": false,
      "last_update_posted_date": "2024-08-01",
      "last_synced_at": "2026-10-23T12:29:05.033Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02780583"
    },
    {
      "nct_id": "NCT01914796",
      "title": "A Phase I Trial to Investigate the Safety and Tolerability of PF-06412562",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF-06412562",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 39,
      "start_date": "2013-08",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-05-23",
      "last_synced_at": "2026-10-23T12:29:05.033Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01914796"
    },
    {
      "nct_id": "NCT01332188",
      "title": "Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "AC-170 0.05%",
          "type": "DRUG"
        },
        {
          "name": "AC-170 0.1%",
          "type": "DRUG"
        },
        {
          "name": "AC-170 0.24%",
          "type": "DRUG"
        },
        {
          "name": "AC-170 0%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aciex Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2011-04",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2017-08-30",
      "last_synced_at": "2026-10-23T12:29:05.033Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01332188"
    },
    {
      "nct_id": "NCT01731938",
      "title": "Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Soft Tissue Surgical Bleeding"
      ],
      "interventions": [
        {
          "name": "Fibrin Sealant (FS) Grifols",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Surgicel®",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Grifols Biologicals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 327,
      "start_date": "2012-11",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2017-02-23",
      "last_synced_at": "2026-10-23T12:29:05.033Z",
      "location_count": 17,
      "location_summary": "Florence, Alabama • Pasadena, California • Bridgeport, Connecticut + 13 more",
      "locations": [
        {
          "city": "Florence",
          "state": "Alabama"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Bridgeport",
          "state": "Connecticut"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01731938"
    },
    {
      "nct_id": "NCT01926782",
      "title": "Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Placebo (for alirocumab)",
          "type": "DRUG"
        },
        {
          "name": "Alirocumab",
          "type": "DRUG"
        },
        {
          "name": "Statin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 803,
      "start_date": "2013-09",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2017-03-21",
      "last_synced_at": "2026-10-23T12:29:05.033Z",
      "location_count": 49,
      "location_summary": "Chandler, Arizona • Goodyear, Arizona • Carmichael, California + 46 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "West Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01926782"
    },
    {
      "nct_id": "NCT02996227",
      "title": "Bilateral Transversus Abdominis Plane Block With Exparel Verus Continuous Epidural Analgesia With Bupivacaine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pain, Postoperative",
        "Major Abdominal Surgery"
      ],
      "interventions": [
        {
          "name": "TAP block",
          "type": "PROCEDURE"
        },
        {
          "name": "Epidural analgesia",
          "type": "PROCEDURE"
        },
        {
          "name": "EXPAREL",
          "type": "DRUG"
        },
        {
          "name": "Bupivacaine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 514,
      "start_date": "2016-12",
      "completion_date": "2019-10",
      "has_results": true,
      "last_update_posted_date": "2024-01-31",
      "last_synced_at": "2026-10-23T12:29:05.033Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02996227"
    },
    {
      "nct_id": "NCT04505566",
      "title": "INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Ketorolac 0.45% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo - Preservative-free artificial tears",
          "type": "DRUG"
        },
        {
          "name": "Aqueous PGE2 and inflammatory cytokines measurements",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Stephen J. Kim, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 164,
      "start_date": "2020-11-09",
      "completion_date": "2026-04-21",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-10-23T12:29:05.033Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04505566"
    },
    {
      "nct_id": "NCT05136053",
      "title": "A Study Investigating Lu AG22515 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Lu AG22515",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Immune System Activator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "19 Years to 60 Years"
      },
      "enrollment_count": 58,
      "start_date": "2022-03-18",
      "completion_date": "2023-08-05",
      "has_results": false,
      "last_update_posted_date": "2023-08-28",
      "last_synced_at": "2026-10-23T12:29:05.033Z",
      "location_count": 2,
      "location_summary": "Long Beach, California • Secaucus, New Jersey",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Secaucus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05136053"
    },
    {
      "nct_id": "NCT04752774",
      "title": "A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Spasticity"
      ],
      "interventions": [
        {
          "name": "Corabotase",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dysport",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 240,
      "start_date": "2021-04-29",
      "completion_date": "2029-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-10-23T12:29:05.033Z",
      "location_count": 5,
      "location_summary": "Downey, California • Overland Park, Kansas • Farmington Hills, Michigan + 2 more",
      "locations": [
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "Elkins Park",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04752774"
    }
  ]
}